AstraZeneca's MedImmune unit acquires AlphaCore Pharma

theflyonthewall.com

AstraZeneca announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme. Financial details of the acquisition were not disclosed.

Rates

View Comments